First Author: E.Beyazyıldız TURKEY
Co Author(s): N. Kocak
Back to previous
To evaluate three treatment modalities for retinopathy of prematurity (ROP)
Samsun Women's and Children's Diseases Hospital, Samsun, Turkey
ROP patients treated with intravitreal anti-vascular endothelial growth factor (anti-VEGF) (Group 1, n=23) (bevacizumab, 0.625 mg /0.025 mL), diode laser photocoagulation (Group 2, n=16) and combined therapy (Group 3, n=9) were retrospectively analysed. Outcome measures were clinical response, recurrence rates and time for complete vascularization of retina.
95 eyes of 48 treated ROP patients analysed in this study. The mean birth weight of groups were 1099 ± 232.2 (510-1980) g in Group 1, 1553 ± 211.3 (790-2300) g in group 2 and 1320 ± 193.1 (700-1800) g in Group 3 and the mean gestational age were 25,8 ± 1.4 (24-32) weeks in Group 1, 29,4 ± 1.2 (24-34) weeks in Group 2 and 26.8 ± 1.4 (23-31) weeks in Group 3. The mean follow-up period was 9.1 months (range). Additional laser treatment was required in 2 patients in Group 1, one patient in Group 2 and one patient in Group 3. Complete regression or non-progression of ROP were achieved in all of the groups. There was no statistically significant difference between recurrence rates in between group (p>0.05). There was a cataract formation (0.5 mm and at the periphery of the pupil) only in one eye of a patient at Group 1. There were no other adverse events occurred. The mean complete vascularization time in group 1 was 75 ± 6.1 weeks of post-menstrual age (PMA).
Intravitreal anti-vascular endothelial administration and diode laser photocoagulation or combined therapy are all effective for treatment of ROP. Complete vascularization of retina may be delayed till 75 weeks of during single anti-VEGF therapy.